Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bumped Kinase Inhibitors Inhibit both Toxoplasma gondii MAPKL1 and CDPK1

23 May 2025

Abstract excerpt

A subset of bumped kinase inhibitors (BKIs) has been optimized to inhibit the calcium dependent protein kinase 1 ( Tg CDPK1; TGGT1_301440) of Toxoplasma gondii and pathogenic Cryptosporidium species. Extensive preclinical development of BKIs has identified BKI-1748 as a highly effective lead compound for toxoplasmosis. Phenotypic and therapeutic effects of BKIs have suggested that BKIs may have targets other than...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy in Disease and Therapy
Share to Parasitic Infections and Diagnostics
Share to Toxoplasma gondii Research Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40407244
DOI: 10.1021/acsinfecdis.5c00051

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bumped Kinase Inhibitors Inhibit both Toxoplasma gondii MAPKL1 and CDPK1PMID 40407244Read ↗

Identification of mutations in TgMAPK1 of Toxoplasma gondii conferring resistance to 1NM-PP1Semantic proximity Read ↗

Inhibition of Calcium Dependent Protein Kinase 1 (CDPK1) by Pyrazolopyrimidine Analogs Decreases Establishment and Reoccurrence of Central Nervous System Disease by Toxoplasma gondiiSemantic proximity Read ↗

A single mutation in the gatekeeper residue in TgMAPKL-1 restores the inhibitory effect of a bumped kinase inhibitor on the cell cycle.Semantic proximity Read ↗

Transcriptional Responses to Bumped Kinase Inhibitor BKI-1708 in <em>Toxoplasma gondii</em> and Human FibroblastsSemantic proximity Read ↗

The gatekeeper residue and beyond: homologous calcium-dependent protein kinases as drug development targets for veterinarian Apicomplexa parasitesSemantic proximity Read ↗

Pyrrolopyrimidine Bumped Kinase Inhibitors for the Treatment of CryptosporidiosisSemantic proximity Read ↗

A Focused Small-Molecule Screen Identifies 14 Compounds with Distinct Effects on Toxoplasma gondiiSemantic proximity Read ↗

The Cryptosporidium parvum KinomeSemantic proximity Read ↗

Use of the Kinase Inhibitor Analog 1NM-PP1 Reveals a Role for Toxoplasma gondii CDPK1 in the Invasion StepSemantic proximity Read ↗

Forward Genetic Screening Identifies a Small Molecule That Blocks Toxoplasma gondii Growth by Inhibiting Both Host- and Parasite-Encoded KinasesSemantic proximity Read ↗

Chemotherapeutics for Toxoplasma gondii: Molecular Biotargets, Binding Modes, and Structure–Activity Relationship InvestigationsSemantic proximity Read ↗

Multiple Determinants for Selective Inhibition of Apicomplexan Calcium-Dependent Protein Kinase CDPK1Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.